Thyroid Oncology Research Unit

Our “Thyroid Oncology Research Unit” at the CEM is dedicated to the comprehensive research and treatment of malignant thyroid diseases. Our mission is to integrate clinical expertise with cutting-edge experimental science to deepen the understanding of these rare but highly complex tumor entities. Central to our work are both the immediate care of our patients and the development of innovative diagnostic and therapeutic approaches.

In our clinical research, we investigate the full spectrum of thyroid cancers – from papillary and follicular thyroid carcinoma to poorly differentiated and anaplastic tumors, as well as medullary thyroid carcinoma. We analyze treatment outcomes, mechanisms of resistance, and the side-effect profiles of modern targeted therapies. A particular focus lies on integrating molecular diagnostics into clinical decision-making and identifying biomarkers that can predict responses to existing and emerging therapies. Our patient cohorts and clinical registries provide a valuable foundation for this work.

In parallel, we conduct intensive experimental research aimed at uncovering the biological mechanisms underlying tumor initiation and progression. We study mechanisms of dedifferentiation and the role of immune-related signaling pathways in aggressive thyroid cancers. Using mouse models, primary cultures, as well as genomic and single-cell analyses, we identify novel therapeutic targets and evaluate innovative treatment strategies. These experimental insights feed directly into translational projects, bridging laboratory discoveries with clinical research.

The strength of our work lies in the close integration of clinical and experimental approaches: clinical observations inspire experimental questions, while laboratory findings help refine therapeutic decisions and guide the design of new studies. Through close collaboration with endocrine surgery, nuclear medicine, and pathology, we create a scientific environment that enables continuous advancement in the diagnosis and treatment of thyroid cancers.

Our goal is to deepen the understanding of the biological mechanisms driving these tumors, improve therapeutic options, and ultimately enhance long-term outcomes for our patients.